Drug intelligence / Profile preview

UGN-103

Development stage: Phase 3
Lead developer: UroGen Pharma
Modality: Small Molecules
Administration: Intravesical

Overview

UGN-103 is an innovative drug formulation of mitomycin being developed for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). It utilizes UroGen's proprietary RTGel technology, a sustained-release, reverse-thermal hydrogel that enables longer exposure of bladder tissue to mitomycin, thereby allowing for non-surgical tumor treatment. The formulation offers potential advantages including a streamlined manufacturing process, simplified reconstitution procedure, and extended intellectual property protection until December 2041.

Other names: UGN-103 (mitomycin) for intravesical solution

Targets

DNA

Beyond the preview

Go deeper on UGN-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UGN-103.

Explore the full profile